eyecro data to be presented at ARVO 2016 in Seattle
Similar Posts
EyeCRO scientists contribute to study published in Experimental Eye Research
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model. Click here to read more
eyecro COO Gives Talk at ARVO
“Dr. Rafal Farjo, Chief Operating Officer of eyecro, gives a seminar to Members-in-Training on Transitioning from Academia to a Start-up. At the 2013 Annual meeting of the Association for Research in vision and Ophthalmology in Seattle.”
Amarantus Announces the Presentation of Data Showing MANF”s Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for Research in Vision and Ophthalmology Annual Meeting, being held in Denver, CO. The results from preclinical studies demonstrate that MANF preserves the light-sensing function of photoreceptor cells in a genetic model of…
EyeCRO conducts successful pre-IND meeting with US Food and Drug Administration to discuss CsA-MIDROPS™
EyeCRO recently requested and conducted a pre-IND meeting with the US FDA to discuss the nonclinical and clinical development plans for CsA-MiDROPS™ to treat Dry Eye Disease. The agency was supportive of the project and agreed that the proposed nonclinical and CMC studies would allow entry into a phase II clinical trial. Also discussed was…
SBIR-STTR Success: Charlesson LLC/EYECRO
Macular Degeneration is the leading cause of blindness and vision loss in people over 50 –and with life expectancies well into the 80s, it is estimated that 1 and 3 elderly individuals will have to deal with this degenerative disease. The remedy? Monthly injections (via needle) into the back of the eye, where the disease…
Once-daily CsA-MiDROPS™ are superior to other CsA drops dosed twice-daily
Ophthalmic distribution studies indicate significantly increased drug concentration with CsA-MiDROPS (Cyclosporine A microemulsion) compared with Restasis. CsA-MiDROPS is well tolerated with little toxicity in a 2-week tolerability study. In the DED model, both 0.05% and 0.1% CsA-MiDROPS conferred a significant effect and were more effective than Restasis for treating experimental DED when dosed twice per…
